August 20, 2018- RAINBOW Study: Antiangiogenic Therapy in Gastric Cancer

The RAINBOW study pre-treated patients with the doublet of fluoropyrimidine plus a platinum, and later gave paclitaxel plus or minus ramucirumab. Survival rates for this study increased to more than 2 months. Another second line study, REGARD lead by Charlie Fuchs, consisted of best supportive care plus a placebo or best supportive care plus ramucirumab. Looking at both studies together we can say that ramucirumab plus paclitaxel is fit for patients in the second line treatment given as the mean survival of the RAINBOW study was around 9 months for the combination.

Treatment Options
View Full Article
Related Videos